We report that the acquisition of tumor aggressiveness in patients is dependent on close associations prevailing between NOS2 and IL-10 synthesis and between IL-17A, TGF-β, and MMP-9 and identifies IL-17A as a possible key predictor of LSCC aggressiveness and resistance to therapy. Here, IL10 is linked to neoplasm.